Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Milestone Pharmaceuticals Inc MIST

Healthcare Biotechnology
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MIST)

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

GlobeNewswire 2 hours ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

GlobeNewswire 7 days ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 4, 2025

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 27, 2025

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

GlobeNewswire February 19, 2025

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

GlobeNewswire February 11, 2025

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

GlobeNewswire January 28, 2025

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 7, 2025

Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire November 25, 2024
View More News ››

Opinion & Analysis (NDAQ:MIST)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MIST)

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Posi

Breaking News: $MIST Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of...
whytestocks - September 6, 2024

Milestone&#xAE; Pharmaceuticals to Participate in a Corporat

BREAKING NEWS: $MIST Milestone&#xAE; Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health...
whytestocks - February 29, 2024

Milestone Pharmaceuticals Announces Pricing of $30.0 Million

Just In: $MIST Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded...
whytestocks - February 29, 2024

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for

News; $MIST Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVTResubmission of NDA expected...
whytestocks - February 26, 2024
View more Bullboard ››

Vista Gold Corp.

Vista Gold Corp.

Vista Gold Corp. (NYSE American and TSX: VGZ) holds the Mt Todd gold project, a shovel-ready development-stage deposit ...
View More »